Seminars in Radiation Oncology
Volume 17, Issue 3 , Pages 176-183 , July 2007

Radioimmunotherapy as a Therapeutic Option for Non-Hodgkin’s Lymphoma

  • Roger M. Macklis, MD

      Affiliations

    • Roger Macklis has received honoraria for teaching and lecturing from Biogen-IDEC and Glaxo-Smith-Kline. Biogen-IDEC has also contributed financial support to the Cleveland Clinic for his investigator-initiated clinical trials in the area of radioimmunotherapy. He has no equity in any involved commercial concern.
    • Corresponding Author InformationAddress reprint requests to Roger M. Macklis, MD, Department of Radiation Oncology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk T28, Cleveland, OH 44195.

References 

  1. Pohlman BL, Sweetenham JW, Macklis RM. Review of clinical radioimmunotherapy. Expert Rev Anticancer Ther. 2006;22:445–462
  2. Davies AJ, Rohatiner AZ, Howell S, et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2004;22:1469–1479
  3. Macklis RM. Radithor and the era of mild radium therapy. JAMA. 1990;264:614–618
  4. Press OW. Radioimmunotherapy for non-Hodgkin’s lymphomas: a historical perspective. Semin Oncol. 2003;30(suppl 4):10–21
  5. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:2453–2463
  6. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–2833
  7. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med. 1993;329:459–465
  8. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17:3793–3803
  9. Leichner PK, Yang NC, Frenkel TL, et al. Dosimetry and treatment planning for 90Y-labeled antiferritin in hepatoma. Int J Radiat Oncol Biol Phys. 1988;14:1033–1042
  10. Mach JP, Buchegger F, Pelegrin A. Progress in Radiolabeled Monoclonal Antibodies for Cancer Diagnosis and Potential for Therapy. Philadelphia: Lippincott; 1989;
  11. Dillehay LE. A model of cell killing by low-dose-rate radiation including repair of sublethal damage, G2 block, and cell division. Radiat Res. 1990;124:201–207
  12. Yorke ED, Wessels BW, Bradley EW. Absorbed dose averages and dose heterogeneities in radioummunotherapy. Antibody Immunoconjugates Radiopharm. 1991;4:623–626
  13. Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin’s lymphoma: A phase II trial in the North Central Cancer Treatment Group. J Clin Oncol. 2005;23:1103–1108
  14. Hernandez MC, Knox SJ. Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2004;59:1274–1287
  15. Macklis RM. How and why does radioimmunotherapy work?. Int J Radiat Oncol Biol Phys. 2004;59:1269–1271
  16. DeNardo SJ. Radioimmunodetection and therapy of breast cancer. Semin Nucl Med. 2005;35:143–151
  17. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974–1981
  18. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457–470
  19. Koral KF, Kaminski MS, Wahl RL. Correlation of tumor radiation-absorbed dose with response is easier to find in previously untreated patients. J Nucl Med. 2003;44:1541–1543author reply 1543
  20. Wiseman GA, Kornmehl E, Leigh B, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: Combined data from 4 clinical trials. J Nucl Med. 2003;44:465–474
  21. Gokhale AS, Mayadev J, Pohlman B, et al. Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy. Int J Radiat Oncol Biol Phys. 2005;63:194–201
  22. Du Y, Honeychurch J, Cragg MS, et al. Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood. 2004;103:1485–1494
  23. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2001;19:3918–3928
  24. Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study. Blood. 2004;103:4429–4431
  25. Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. J Nucl Med. 2005;46(suppl 1):4S–12S
  26. O’Keefe TL, Williams GT, Davies SL, et al. Mice carrying a CD20 gene disruption. Immunogenetics. 1998;48:125–132
  27. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother. 2000;48:673–683
  28. Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis. 2000;26:133–143
  29. Li H, Ayer LM, Lytton J, et al. Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem. 2003;278:42427–42434
  30. Bellosillo B, Villamor N, Lopez-Guillermo A, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood. 2001;98:2771–2777
  31. Hainsworth JD, Litchy S, Burris HA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin’s lymphoma. J Clin Oncol. 2002;20:4261–4267
  32. Czuczman MS, Weaver R, Alkuzweny B, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004;22:4711–4716
  33. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin’s lymphoma. J Clin Oncol. 2003;21:1263–1270
  34. Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol. 2005;23:712–719
  35. Gregory SA, Leonard JP, Knox SJ. The iodine 131I tositumomab therapeutic regimen: summary of safety in 995 patients with relapsed/refractory low-grade (LG) and transformed LG non-Hodgkin’s lymphoma. Proc Am Soc Clin Oncol. 2004;22:6732;abstract
  36. Sweetenham JW, Dicke K, Arcaroli J. Efficacy and safety of Yttrium 90 (90Y) Ibritumomab tiuxetan (Zevalin) therapy with rituximab maintenance in patients wtih untreated low-grade follicular lymphoma. Blood. 2004;104:720;abstract
  37. Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 2005;105:4576–4582
  38. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2000;18:1316–1323
  39. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood. 2002;99:4336–4342
  40. Cheson BD. The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma. BioDrugs. 2005;19:309–322
  41. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242
  42. Pfreundschuh M, Truemper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–391
  43. Kahl BS. Treatment of indolent lymphomas in the era of targeted therapy. Clin Adv Hematol Oncol. 2006;4:6–7
  44. Nademanee A, Forman S, Molina A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood. 2005;106:2896–2902
  45. Vose JM, Bierman PJ, Enke C, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:461–467
  46. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:496–498
  47. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2934–2942

PII: S1053-4296(07)00014-8

doi: 10.1016/j.semradonc.2007.02.003

Seminars in Radiation Oncology
Volume 17, Issue 3 , Pages 176-183 , July 2007

Article Tools

* Image Usage & Resolution